{
  "functional_evidence_assessment": [
    {
      "variant_id": {
        "Gene": "SNCA",
        "Protein_Change": {
          "ref": "A",
          "alt": "T",
          "position": "30"
        },
        "variant_string_id": "SNCA A30T"
      },
      "functional_evidence_aim": "Pathogenic",
      "assessment_steps": [
        {
          "step_name": "Step 1: Define the disease mechanism",
          "extracted_paper_info": "The paper describes Parkinson's disease (PD) as involving the loss of dopaminergic neurons and the presence of Lewy bodies containing aggregated proteins, with a-synuclein playing a key role in neurotoxicity.",
          "judgment": "Yes",
          "reasoning": "The paper clearly links a-synuclein aggregation to PD pathology, providing a disease mechanism relevant to the functional assays."
        },
        {
          "step_name": "Step 2: Evaluate applicability of general classes of assay used in the field",
          "extracted_paper_info": "The study uses proteasomal degradation assays to evaluate the effect of HO-1 overexpression on a-synuclein levels, including the A30P mutant.",
          "judgment": "Yes",
          "reasoning": "Proteasomal degradation is a relevant assay class for studying protein aggregation diseases like PD, as it directly relates to the clearance of misfolded proteins.",
          "next_step_or_outcome": "Proceed to Step 3"
        },
        {
          "step_name": "Step 3: Evaluate validity of specific instances of assays",
          "extracted_paper_info": "The study includes controls for HO-1 expression levels and uses proteasome inhibitors (lactacystin and MG132) to validate the specificity of a-synuclein degradation pathways.",
          "judgment": "Yes",
          "reasoning": "Basic controls and replicates are mentioned, including the use of specific inhibitors to confirm the proteasomal degradation pathway.",
          "next_step_or_outcome": "Proceed to Sub-step 3c"
        },
        {
          "step_name": "Sub-step 3c: Variant Controls",
          "extracted_paper_info": "The study compares the degradation of wild-type a-synuclein with the A30P mutant, showing that the mutant is resistant to HO-1-induced proteosomal degradation.",
          "judgment": "Yes",
          "reasoning": "The use of wild-type a-synuclein as a control and the demonstration of differential degradation between wild-type and mutant forms provide variant controls.",
          "next_step_or_outcome": "Proceed to Step 4"
        },
        {
          "step_name": "Step 4: Apply evidence to individual variant interpretation",
          "extracted_paper_info": "The study demonstrates that the A30P mutation renders a-synuclein resistant to proteosomal degradation, which is linked to PD pathology.",
          "judgment": "Yes",
          "reasoning": "The data supports a pathogenic role for the A30P mutation by showing its resistance to degradation, contributing to protein aggregation.",
          "next_step_or_outcome": "Proceed to Sub-step 4b"
        },
        {
          "step_name": "Sub-step 4b: No OddsPath Calculation",
          "extracted_paper_info": "The study does not provide statistical analyses sufficient to calculate OddsPath but demonstrates significant differences in degradation rates between wild-type and mutant a-synuclein.",
          "judgment": "Yes",
          "reasoning": "While OddsPath is not calculated, the study provides clear evidence of the mutant's resistance to degradation, supporting a pathogenic interpretation.",
          "next_step_or_outcome": "Max PS3_moderate"
        }
      ],
      "final_evidence_strength": {
        "type": "Pathogenic",
        "strength": "PS3_moderate"
      },
      "overall_conclusion": "The A30P mutation in a-synuclein shows resistance to proteosomal degradation induced by HO-1, supporting its pathogenic role in PD through impaired protein clearance."
    },
    {
      "variant_id": {
        "Gene": "SNCA",
        "Protein_Change": {
          "ref": "A",
          "alt": "T",
          "position": "53"
        },
        "variant_string_id": "SNCA A53T"
      },
      "functional_evidence_aim": "Pathogenic",
      "assessment_steps": [
        {
          "step_name": "Step 1: Define the disease mechanism",
          "extracted_paper_info": "The paper describes Parkinson's disease (PD) as involving the loss of dopaminergic neurons and the presence of Lewy bodies containing aggregated proteins, with a-synuclein playing a key role in neurotoxicity.",
          "judgment": "Yes",
          "reasoning": "The paper clearly links a-synuclein aggregation to PD pathology, providing a disease mechanism relevant to the functional assays."
        },
        {
          "step_name": "Step 2: Evaluate applicability of general classes of assay used in the field",
          "extracted_paper_info": "The study uses proteasomal degradation assays to evaluate the effect of HO-1 overexpression on a-synuclein levels, including the A53T mutant.",
          "judgment": "Yes",
          "reasoning": "Proteasomal degradation is a relevant assay class for studying protein aggregation diseases like PD, as it directly relates to the clearance of misfolded proteins.",
          "next_step_or_outcome": "Proceed to Step 3"
        },
        {
          "step_name": "Step 3: Evaluate validity of specific instances of assays",
          "extracted_paper_info": "The study includes controls for HO-1 expression levels and uses proteasome inhibitors (lactacystin and MG132) to validate the specificity of a-synuclein degradation pathways.",
          "judgment": "Yes",
          "reasoning": "Basic controls and replicates are mentioned, including the use of specific inhibitors to confirm the proteasomal degradation pathway.",
          "next_step_or_outcome": "Proceed to Sub-step 3c"
        },
        {
          "step_name": "Sub-step 3c: Variant Controls",
          "extracted_paper_info": "The study compares the degradation of wild-type a-synuclein with the A53T mutant, showing that the mutant does not significantly affect a-synuclein degradation in HO-1 over-expressing cells.",
          "judgment": "Yes",
          "reasoning": "The use of wild-type a-synuclein as a control and the demonstration of similar degradation rates between wild-type and mutant forms provide variant controls.",
          "next_step_or_outcome": "Proceed to Step 4"
        },
        {
          "step_name": "Step 4: Apply evidence to individual variant interpretation",
          "extracted_paper_info": "The study demonstrates that the A53T mutation does not significantly affect a-synuclein degradation, suggesting a different mechanism of pathogenicity compared to A30P.",
          "judgment": "Yes",
          "reasoning": "The data suggests that the A53T mutation may contribute to PD pathology through mechanisms other than resistance to proteosomal degradation.",
          "next_step_or_outcome": "Proceed to Sub-step 4b"
        },
        {
          "step_name": "Sub-step 4b: No OddsPath Calculation",
          "extracted_paper_info": "The study does not provide statistical analyses sufficient to calculate OddsPath but demonstrates no significant difference in degradation rates between wild-type and A53T mutant a-synuclein.",
          "judgment": "Yes",
          "reasoning": "While OddsPath is not calculated, the study provides clear evidence that the A53T mutation does not impair degradation, suggesting a different pathogenic mechanism.",
          "next_step_or_outcome": "Max PS3_supporting"
        }
      ],
      "final_evidence_strength": {
        "type": "Pathogenic",
        "strength": "PS3_supporting"
      },
      "overall_conclusion": "The A53T mutation in a-synuclein does not significantly affect proteosomal degradation, suggesting its pathogenic role in PD may involve mechanisms other than impaired protein clearance."
    }
  ]
}